Eye injection burden varies by disease, study finds
NCT ID NCT07514559
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study looked at how much of a burden patients feel from repeated anti-VEGF eye injections for three different eye diseases: wet age-related macular degeneration, retinal vein occlusion, and diabetic macular edema. Researchers surveyed 393 patients about their treatment burden, socioeconomic status, and demographics. The goal was to identify factors that might affect whether patients stick with their treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- anti-VEGF (vascular endothelial growth factor) injections
- What this could lead to
- If successful, this could help doctors understand which patient groups struggle most with treatment burden, leading to better support and adherence.
- What could go wrong
- This is an observational study that measures patient perceptions, not a treatment trial. It cannot prove that changing anything will improve outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGE-RELATED MACULAR DEGENERATION (ARMD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hietzing Hospital
Vienna, 1130, Austria
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could eye drops replace injections for a leading cause of blindness?
- Can a new eye injection beat the current standard for diabetic vision loss?
- Higher-Dose eye injection may help wet AMD patients who Didn't respond to standard treatments
- AI could predict which eye treatments work best for Diabetes-Related vision loss
- New eye drug EYE103 takes on lucentis in major trial for Diabetes-Related vision loss
- New dosing strategy could mean fewer eye injections for Diabetes-Related vision loss